The SORTT Solution: Helping to Reduce Eye Tissue Toxicity after Radiation
By consensus among medical physicists, radiation therapists, and ophthalmic oncologists, the Study of Ophthalmic Radiation Therapy Toxicity (SORTT) collects data that captures the 8th edition of the TNM ocular staging, methods of radiation treatments, and short-term outcomes related to the eyelids, follicles, conjunctiva, cornea, iris, lens, retina, choroid, optic nerve, and lacrimal system.
The collected data will be used as a basis to correlate the SORTT grading systems with treatment as well as to develop preferred radiation practice patterns for the treatment of ocular tumours that minimize ophthalmic toxicity.
Over the past 4 years, TECHNA’s Yuliya Gavrylyuk has worked closely with the ocular oncology clinical team to plan, define, and document the requirements as well as oversee the development of the SORTT system, and lead its implementation. Yuliya also manages the Institutional Review Board (IRB) processes and contracts for the SORTT participating sites.
To date, 11 centres have received the Research Ethics Board approval and are now enrolling patients, including:
- Princess Margaret Cancer Centre, Toronto
- New York Eye and Ear Infirmary of Mount Sinai, New York, NY
- Emory University, Atlanta, GA
- Jude Children’s Research Hospital, Memphis, TN
- The University of Southern California, Los Angeles, CA
- Helmholtz Eye Institute, Moscow, Russia
- King Hussein Cancer Center, Amman, Jordan
- Calle Ophthalmic and Orbit Center Shaio Clinic, Bogota, Colombia
- Centre Antoine Lacassagne, Nice University Hospital, Nice, France
- National Cancer Center, Japan
- University of Alberta
In addition, 15 more centres are in the process of compiling documentation required to join the study.
SORTT uses the eCancerCare platform. eCancerCare is a suite of web-based software tools that streamlines the collection of high-quality data for disease management and research. eCancerCare software was developed by the Health Informatics Research (HIR) team at TECHNA.